Understanding the link between inflammation and cancer
When colorectal surgeon and researcher Emina Huang, MD, joined Cleveland Clinic’s staff in August 2013, she brought along two five-year NIH R01 grants with remaining funding totaling $1.5 million. The monies support her groundbreaking research into the pathogenesis of inflammatory associated colorectal cancer.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The relationship between chronic inflammation and cancer development is well-known, but the cellular and molecular mechanisms underlying this relationship are not well-understood. We suspect that increased levels of the inflammation-causing protein interleukin-8 (IL-8) may be partly to blame for increased rates of colon cancer in patients with ulcerative colitis. Our long-term goal is to clarify the link between inflammation and cancer in general, and to prevent colitis-associated cancer (CAC) in particular.
In this project, we are examining the contribution of the microenvironment to inflammatory- associated cancer. Our immediate objective is to determine the roles of genetic defects, cancer stem cells and stromal fibroblasts in the generation of colon cancer-initiating cells. Our central hypothesis is that these three factors are key to CAC development. Proving this hypothesis will facilitate the development of novel strategies to prevent CAC and substantially improve our ability to predict which patients will progress to malignancy.
Up to 18 percent of patients with chronic ulcerative colitis develop colorectal cancer. This project focuses on why epithelial cells make IL-8, and what effect the protein has on the development of cancer. Is it creating the angiogenic switch by making VEGF downstream and usurping the local vessels to feed itself? If IL-8 is the culprit in cancer formation, we can focus on finding ways to regulate its function to prevent inflammation-associated cancer, and specifically, colorectal cancer. Our approach is innovative, because we have unique tools, including colitis-derived colon cancer-initiating cells (CCICs), and are using CCICs from sporadic colorectal cancer for comparison. Our central hypothesis is that IL-8 signaling is required for the colitis-to-cancer transition. Once we understand the contribution and mechanism by which IL-8 promotes tumor initiation, we will be able to develop ways to interfere with the progression from benign colitis to malignant cancer.
Several of my colleagues are studying colitis-associated cancer, but from different angles. Others are studying inflammatory bowel disease or colorectal cancer. We will be discussing ways to dovetail our research in order to more quickly gain an understanding of the mechanisms that promote the development of colorectal cancer and develop novel ways to prevent this devastating disease.
Dr. Huang can be reached at 216.445.4631 or huange2@ccf.org.
First-of-its-kind clinic for immune-related adverse events supports oncologists in managing severe side effects
Novel therapy “retrains” the brain to disrupt pain signals
An underdiagnosed condition in patients with cancer
Study demonstrates superior visualization of occult primary lesions
New device offers greater tumor control for malignant liver lesions
Cleveland Clinic researchers discover what drives – and what may halt – virus-induced cancer
First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention
New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function